Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial

V. L. Hansen, N. Gabrail, J. Levin, R. Bandekar, Jørn Herrstedt

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskning

OriginalsprogEngelsk
Publikationsdato2008
StatusUdgivet - 2008
BegivenhedASCO Gastrointestinal Cancers Symposium - Florida, USA
Varighed: 25. jan. 200827. jan. 2008

Konference

KonferenceASCO Gastrointestinal Cancers Symposium
LandUSA
ByFlorida
Periode25/01/200827/01/2008

Citer dette

Hansen, V. L., Gabrail, N., Levin, J., Bandekar, R., & Herrstedt, J. (2008). Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial. Poster session præsenteret på ASCO Gastrointestinal Cancers Symposium, Florida, USA.
Hansen, V. L. ; Gabrail, N. ; Levin, J. ; Bandekar, R. ; Herrstedt, Jørn. / Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial. Poster session præsenteret på ASCO Gastrointestinal Cancers Symposium, Florida, USA.
@conference{18b4d7a0a02211dd9b31000ea68e967b,
title = "Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial",
author = "Hansen, {V. L.} and N. Gabrail and J. Levin and R. Bandekar and J{\o}rn Herrstedt",
year = "2008",
language = "English",
note = "null ; Conference date: 25-01-2008 Through 27-01-2008",

}

Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial. / Hansen, V. L.; Gabrail, N.; Levin, J.; Bandekar, R.; Herrstedt, Jørn.

2008. Poster session præsenteret på ASCO Gastrointestinal Cancers Symposium, Florida, USA.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskning

TY - CONF

T1 - Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double-blind, placebo-controlled phase II trial

AU - Hansen, V. L.

AU - Gabrail, N.

AU - Levin, J.

AU - Bandekar, R.

AU - Herrstedt, Jørn

PY - 2008

Y1 - 2008

M3 - Poster

ER -